Literature DB >> 35084566

Joining the dots: Answers.

Niladri Bose1, Kaustabh Chaudhuri2, Mordi Muorah3, Rajiv Sinha4,5.   

Abstract

Entities:  

Keywords:  Acute kidney injury; Acute liver failure; Deferasirox; Iron chelation therapy; Pharmacogenomics; Renal tubular acidosis

Year:  2022        PMID： 35084566     DOI： 10.1007/s00467-021-05415-y

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN： 0931-041X            Impact factor:   3.714


× No keyword cloud information.
  12 in total

Review 1.  Pharmacogenomics: translating functional genomics into rational therapeutics.

Authors:  W E Evans; M V Relling
Journal:  Science       Date:  1999-10-15       Impact factor: 47.728

2.  Comprehensive analysis of UGT1A polymorphisms predictive for pharmacokinetics and treatment outcome in patients with non-small-cell lung cancer treated with irinotecan and cisplatin.

Authors:  Ji-Youn Han; Hyeong-Seok Lim; Eun Soon Shin; Yeon-Kyeong Yoo; Yong Hoon Park; Jong-Eun Lee; In-Jin Jang; Dae Ho Lee; Jin Soo Lee
Journal:  J Clin Oncol       Date:  2006-04-24       Impact factor: 44.544

Review 3.  Genetic polymorphisms of ATP-binding cassette transporters ABCB1 and ABCG2: therapeutic implications.

Authors:  Aki Sakurai; Ai Tamura; Yuko Onishi; Toshihisa Ishikawa
Journal:  Expert Opin Pharmacother       Date:  2005-11       Impact factor: 3.889

4.  Genotype-directed, dose-finding study of irinotecan in cancer patients with UGT1A1*28 and/or UGT1A1*6 polymorphisms.

Authors:  Taroh Satoh; Takashi Ura; Yasuhide Yamada; Kentaro Yamazaki; Toshimasa Tsujinaka; Masaki Munakata; Tomohiro Nishina; Shu Okamura; Taito Esaki; Yasutsuna Sasaki; Wasaburo Koizumi; Yoshihiro Kakeji; Naoki Ishizuka; Ichinosuke Hyodo; Yuh Sakata
Journal:  Cancer Sci       Date:  2011-08-12       Impact factor: 6.716

5.  Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: efficacy and safety during 5 years' follow-up.

Authors:  M Domenica Cappellini; Mohamed Bejaoui; Leyla Agaoglu; Duran Canatan; Marcello Capra; Alan Cohen; Guillermo Drelichman; Marina Economou; Slaheddine Fattoum; Antonis Kattamis; Yurdanur Kilinc; Silverio Perrotta; Antonio Piga; John B Porter; Louis Griffel; Victor Dong; Joan Clark; Yesim Aydinok
Journal:  Blood       Date:  2011-05-31       Impact factor: 22.113

Review 6.  Renal tubular acidosis.

Authors:  J Rodríguez-Soriano; A Vallo
Journal:  Pediatr Nephrol       Date:  1990-05       Impact factor: 3.714

Review 7.  Relevance of UDP-glucuronosyltransferase polymorphisms for drug dosing: A quantitative systematic review.

Authors:  J C Stingl; H Bartels; R Viviani; M L Lehmann; J Brockmöller
Journal:  Pharmacol Ther       Date:  2013-09-27       Impact factor: 12.310

8.  Hyperchloremic metabolic acidosis due to deferasirox in a patient with beta thalassemia major.

Authors:  Nikolaos Papadopoulos; Aresti Vasiliki; Georgios Aloizos; Petros Tapinis; Athanasios Kikilas
Journal:  Ann Pharmacother       Date:  2009-11-24       Impact factor: 3.154

9.  ABCC2 c.-24 C>T single-nucleotide polymorphism was associated with the pharmacokinetic variability of deferasirox in Chinese subjects.

Authors:  Kangna Cao; Guanghui Ren; Chengcan Lu; Yao Wang; Yanan Tan; Jing Zhou; Yongjie Zhang; Yang Lu; Ning Li; Xijing Chen; Di Zhao
Journal:  Eur J Clin Pharmacol       Date:  2019-11-01       Impact factor: 2.953

10.  What is known about deferasirox chelation therapy in pediatric HSCT recipients: two case reports of metabolic acidosis.

Authors:  Carmen Fucile; Francesca Mattioli; Valeria Marini; Massimo Gregori; Aurelio Sonzogni; Antonietta Martelli; Natalia Maximova
Journal:  Ther Clin Risk Manag       Date:  2018-09-07       Impact factor: 2.423
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.